Colitis-associated neoplasia: Molecular basis and clinical translation

Cellular and Molecular Life Sciences

Volumn 71, Issue 18, 2014, Pages 3523-3535

  Foersch, Sebastian ^a   Neurath, Markus F ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Chemoprevention; Colitis associated cancer; Colorectal carcinoma; Crohn's disease; Endoscopy; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; AMINOSALICYLIC ACID DERIVATIVE; BEVACIZUMAB; GLUCOCORTICOID; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 10; SALAZOSULFAPYRIDINE; STAT3 PROTEIN; TOCILIZUMAB; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; VASCULOTROPIN;

ANTIOXIDANT ACTIVITY; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLITIS; COLITIS ASSOCIATED CANCER; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONFOCAL LASER MICROSCOPY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DOSE RESPONSE; DRUG TARGETING; EARLY DIAGNOSIS; EPIGENETICS; GASTROINTESTINAL ENDOSCOPY; GENE MUTATION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INTESTINE FLORA; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

CHEMOPREVENTION; COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MICROBIOTA; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906939266     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1636-x     Document Type: Review

References (160)

1. Crohn B, Rosenberg H (1925) The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 170:220-228
2. Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323:1228-1233 (Pubitemid 20366527)
3. Jess T, Gamborg M, Matzen P et al (2005) Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100:2724-2729
4. Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526-535 (Pubitemid 32234798)
5. Rutter MD, Saunders BP, Wilkinson KH et al (2006) Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. YGAST 130:1030-1038
6. Soetikno RM, Lin OS, Heidenreich PA et al (2002) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56:48-54 (Pubitemid 41115048)
7. Velayos FS, Loftus EV, Jess T et al (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. YGAST 130:1941-1949 (Pubitemid 43816957)
8. Lashner BA, Turner BC, Bostwick DG et al (1990) Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci 35:349-352 (Pubitemid 20069531)
9. Lukas M (2010) Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis 28:619-624
10. Cho KR, Vogelstein B (1992) Genetic alterations in the adenoma-carcinoma sequence. Cancer 70:1727-1731
11. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789-799 (Pubitemid 39070849)
12. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87(2):159-170 (Pubitemid 26358996)
13. Su LK, Kinzler KW, Vogelstein B et al (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (New York, NY) 256:668-670
14. Powell SM, Zilz N, Beazer-Barclay Y et al (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359:235-237. doi:10.1038/359235a0
15. Foersch S, Waldner MJ, Neurath MF (2012) Colitis and colorectal cancer. Dig Dis 30:469-476
16. Kern SE, Redston M, Seymour AB et al (1994) Molecular genetic profiles of colitis-associated neoplasms. YGAST 107:420-428 (Pubitemid 24233316)
17. Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15-16. doi:10.1038/358015a0
18. Gondek LP, Tiu R, O'Keefe CL et al (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:1534-1542. doi:10.1182/blood-2007-05-092304 (Pubitemid 351213443)
19. Burmer GC, Rabinovitch PS, Haggitt RC et al (1992) Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. YGAST 103:1602-1610
20. Hussain SP, Amstad P, Raja K et al (2000) Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60:3333-3337 (Pubitemid 30482141)
21. Brentnall TA, Crispin DA, Rabinovitch PS et al (1994) Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. YGAST 107:369-378 (Pubitemid 24233310)
22. Cooks T, Pateras IS, Tarcic O et al (2013) Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23:634-646. doi:10.1016/j.ccr.2013.03.022
23. Tarmin L, Yin J, Harpaz N et al (1995) Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 55:2035-2038
24. Fogt F, Vortmeyer AO, Goldman H et al (1998) Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Hum Pathol 29:131-136 (Pubitemid 28099507)
25. Cooper HS, Everley L, Chang W et al (2001) The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 121:1407-1416. doi:10.1053/gast.2001. 29609 (Pubitemid 33140458)
26. Leedham S, Graham T, Oukrif D (2009) Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 136(542):550.e6. doi:10.1053/j.gastro.2008.10.086
27. Brown JB, Lee G, Managlia E et al (2010) Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology 138:595-605, 605.e1-3. doi:10.1053/j.gastro.2009.10.038
28. Lee G, Goretsky T, Managlia E et al (2010) Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139:869. doi:10.1053/j.gastro. 2010.05.037
29. Pozzi A, Yan X, Macias-Perez I et al (2004) Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 279:29797-29804. doi:10.1074/jbc.M313989200 (Pubitemid 38915863)
30. Tessner TG, Muhale F, Riehl TE et al (2004) Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 114:1676-1685. doi:10.1172/JCI22218 (Pubitemid 40385559)
31. Rapozo DCM, Grinmann AB, Carvalho ATP et al (2009) Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease. Int J Colorectal Dis 24:1141-1148. doi:10.1007/s00384-009-0748-5
32. Lang SM, Stratakis DF, Heinzlmann M et al (1999) Molecular screening of patients with long standing extensive ulcerative colitis: detection of p53 and Ki-ras mutations by single strand conformation polymorphism analysis and differential hybridisation in colonic lavage fluid. Gut 44:822-825 (Pubitemid 29244218)
33. Umetani N, Sasaki S, Masaki T et al (2000) Involvement of APC and K-ras mutation in non-polypoid colorectal tumorigenesis. Br J Cancer 82:9-15. doi:10.1054/bjoc.1999.0868 (Pubitemid 30008951)
34. Itzkowitz SH (2006) Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 35:553-571
35. Rashid A, Hamilton SR (1997) Genetic alterations in sporadic and Crohn's-associated adenocarcinomas of the small intestine. Gastroenterology 113:127-135 (Pubitemid 27281766)
36. Hofseth LJ, Saito S, Hussain SP et al (2003) Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 100:143-148 (Pubitemid 36078042)
37. Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev Cancer 3:276-285. doi:10.1038/nrc1046 (Pubitemid 37328863)
38. Westbrook AM, Wei B, Braun J, Schiestl RH (2009) Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res 69:4827-4834. doi:10.1158/0008-5472.CAN-08-4416
39. Ferguson LR (2010) Chronic inflammation and mutagenesis. Mutat Res 690:3-11. doi:10.1016/j.mrfmmm.2010.03.007
40. Cook PJ, Ju BG, Telese F et al (2009) Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458:591-596. doi:10.1038/nature07849
41. Shaked H, Hofseth LJ, Chumanevich A et al (2012) Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci USA 109:14007-14012. doi:10.1073/pnas.1211509109
42. Erdman SE, Rao VP, Poutahidis T et al (2009) Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc Natl Acad Sci USA 106:1027-1032. doi:10.1073/pnas.0812347106
43. Goodman JE, Hofseth LJ, Hussain SP, Harris CC (2004) Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 44:3-9. doi:10.1002/em.20024 (Pubitemid 38982068)
44. Bonner WM, Redon CE, Dickey JS et al (2008) GammaH2AX and cancer. Nat Rev Cancer 8:957-967. doi:10.1038/nrc2523
45. Risques RA, Lai La, Brentnall Ta et al (2008) Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology 135:410-418. doi:10.1053/j.gastro.2008.04.008
46. O'Sullivan JN, Bronner MP, Brentnall Ta et al (2002) Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 32:280-284. doi:10.1038/ng989
47. O'Sullivan J, Risques RA, Mandelson MT et al (2006) Telomere length in the colon declines with age: a relation to colorectal cancer? Cancer Epidemiol Biomarkers Prev 15:573-577. doi:10.1158/1055-9965.EPI-05-0542
48. Wirtz S, Neufert C, Weigmann B, Neurath MF (2007) Chemically induced mouse models of intestinal inflammation. Nat Protoc 2:541-546 (Pubitemid 47040018)
49. Neurath MF, Finotto S (2009) Translating inflammatory bowel disease research into clinical medicine. Immunity 31:357-361. doi:10.1016/j.immuni.2009. 08.016
50. Amit S, Ben-Neriah Y (2003) NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 13:15-28 (Pubitemid 36269177)
51. Greten FR, Eckmann L, Greten TF et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-296. doi:10.1016/j.cell.2004.07.013 (Pubitemid 39061110)
52. Greten FR, Arkan MC, Bollrath J et al (2007) NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130:918-931 (Pubitemid 47332565)
53. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F et al (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229-241 (Pubitemid 38962578)
54. Waldner MJ, Foersch S, Neurath MF (2012) Interleukin-6 - a key regulator of colorectal cancer development. Int J Biol Sci 8:1248-1253
55. Yamamoto K, Rose-John S (2012) Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin Pharmacol Ther 91:574-576. doi:10.1038/clpt.2012.11
56. Neurath MF, Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83-89. doi:10.1016/j.cytogfr.2011.02.003
57. Jarnicki A, Putoczki T, Ernst M (2010) Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div 5:14. doi:10.1186/1747-1028-5-14
58. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809. doi:10.1038/nrc2734
59. Waldner MJ, Wirtz S, Jefremow A et al (2010) VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 207:2855-2868
60. Grivennikov S, Karin E, Terzic J et al (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103-113. doi:10.1016/j.ccr.2009.01.001
61. Grivennikov S, Karin M (2008) Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13:7-9. doi:10.1016/j.ccr.2007.12.020 (Pubitemid 350309747)
62. Putoczki TL, Thiem S, Loving A et al (2013) Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24:257-271. doi:10.1016/j.ccr.2013.06.017
63. Chung Y-C, Chang Y-F (2003) Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 50:1910-1913 (Pubitemid 37467960)
64. Tanaka T, Narazaki M, Kishimoto T (2012) Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52:199-219. doi:10.1146/annurev-pharmtox-010611-134715
65. Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462-2476. doi:10.1056/NEJMoa050516 (Pubitemid 41770166)
66. Popivanova BK, Kitamura K, Wu Y et al (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:560-570 (Pubitemid 351206546)
67. Kim YJ, Hong KS, Chung JW et al (2010) Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev Res (Phila) 3:1314-1333. doi:10.1158/1940-6207.CAPR-09-0272
68. Berg DJ, Davidson N, Kühn R et al (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98:1010-1020. doi:10.1172/JCI118861 (Pubitemid 26293320)
69. Rennick DM, Fort MM, Davidson NJ (1997) Studies with IL-10-/- mice: an overview. J Leukoc Biol 61:389-396
70. Kühn R, Löhler J, Rennick D et al (1993) Interleukin-10- deficient mice develop chronic enterocolitis. Cell 75:263-274
71. Grütz G (2005) New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 77:3-15. doi:10.1189/jlb.0904484
72. Franke A, Balschun T, Karlsen TH et al (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40:1319-1323. doi:10.1038/ng.221
73. Danese S (2012) New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61:918-932. doi:10.1136/gutjnl-2011-300904
74. Sturlan S, Oberhuber G, Beinhauer BG et al (2001) Interleukin-10- deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 22:665-671 (Pubitemid 32288669)
75. Buonocore S, Ahern PP, Uhlig HH et al (2010) Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464:1371-1375. doi:10.1038/nature08949
76. Yen D, Cheung J, Scheerens H et al (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116:1310-1316. doi:10.1172/JCI21404
77. Grivennikov SI, Wang K, Mucida D et al (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491:254-258. doi:10.1038/nature11465
78. Langowski JL, Zhang X, Wu L et al (2006) IL-23 promotes tumour incidence and growth. Nature 442:461-465. doi:10.1038/nature04808 (Pubitemid 44264796)
79. Hinoi T, Akyol A, Theisen BK et al (2007) Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 67:9721-9730. doi:10.1158/0008-5472.CAN-07-2735 (Pubitemid 47621219)
80. Hurwitz HI, Yi J, Ince W et al (2009) The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14:22-28
81. Costa C, Incio J, Soares R (2007) Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10:149-166 (Pubitemid 47305203)
82. Yoo S-A, Kwok S-K, Kim W-U (2008) Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008:129873
83. Scaldaferri F, Vetrano S, Sans M et al (2009) VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 136(585):595.e5
84. Jänne PA, Mayer RJ (2000) Chemoprevention of colorectal cancer. N Engl J Med 342:1960-1968
85. Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1:11-21. doi:10.1038/35094017 (Pubitemid 33741877)
86. Raju R, Cruz-Correa M (2006) Chemoprevention of colorectal cancer. Dis Colon Rectum 49:113-115
87. Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100(6):1345-1353 (Division of Gastroenterology and UCSF Center for Colitis and Crohn's Disease, University of California, San Francisco, California 94143, USA)
88. Rubin DT, Cruz-Correa MR, Gasche C et al (2008) Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 14:265-274. doi:10.1002/ibd. 20297 (Pubitemid 351288050)
89. Ishikawa T-O, Herschman HR (2010) Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 31:729-736. doi:10.1093/carcin/bgq002
90. Waldner MJ, Neurath MF (2009) Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 31:249-256. doi:10.1007/s00281- 009-0161-8
91. Mangerich A, Knutson CG, Parry NM, et al. (2012) Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. http://www.pnas.org/cgi/doi/10.1073/ pnas.1207829109
92. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417-429. doi:10.1056/NEJMra020831
93. Shibata M, Nezu T, Kanou H et al (2002) Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 34:416-420 (Pubitemid 34258317)
94. Pagès F, Berger A, Camus M et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666. doi:10.1056/NEJMoa051424
95. Kettunen HL, Kettunen ASL, Rautonen NE (2003) Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res 63:5136-5142 (Pubitemid 37022655)
96. Wolf D, Wolf AM, Rumpold H et al (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11:8326-8331. doi:10.1158/1078- 0432.CCR-05-1244 (Pubitemid 41746944)
97. Erdman SE, Sohn JJ, Rao VP et al (2005) CD4+ CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65:3998-4004. doi:10.1158/0008-5472.CAN-04-3104 (Pubitemid 40775635)
98. Erdman SE, Poutahidis T (2010) Roles for inflammation and regulatory T cells in colon cancer. Toxicol Pathol 38:76-87. doi:10.1177/0192623309354110
99. Mu{combining double acute accent}zes G, Molnár B, Sipos F (2012) Regulatory T cells in inflammatory bowel diseases and colorectal cancer. World J Gastroenterol 18:5688-5694. doi:10.3748/wjg.v18.i40.5688
100. Clevers H (2004) At the crossroads of inflammation and cancer. Cell 118:671-674
101. Barker N, van Es JH, Kuipers J et al (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449:1003-1007 (Pubitemid 350014593)
102. Sato T, Vries RG, Snippert HJ et al (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459:262-265
103. Barker N, Ridgway RA, van Es JH et al (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457:608-611
104. Schwitalla S, Fingerle Aa, Cammareri P et al (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152:25-38. doi:10.1016/j.cell.2012.12.012
105. Neufert C, Becker C, Türeci Ö et al (2013) Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest 123:1428-1443. doi:10.1172/JCI63748
106. Guarner F, Malagelada J-R (2003) Gut flora in health and disease. Lancet 361:512-519. doi:10.1016/S0140-6736(03)12489-0 (Pubitemid 36173720)
107. Cho I, Blaser MJ (2012) The human microbiome: at the interface of health and disease. Nat Rev Genet 13:260-270. doi:10.1038/nrg3182
108. Rous P, Beard JW (1935) The progression to carcinoma of virus-induced rabbit papillomas (SHOPE). J Exp Med 62:523-548
109. Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13:800-812. doi:10.1038/nrc3610
110. Li Y, Kundu P, Seow SW et al (2012) Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APC-Min/+ mice. Carcinogenesis 33:1231-1238. doi:10.1093/carcin/bgs137
111. Strober W, Fuss IJ (2006) Experimental models of mucosal inflammation. Adv Exp Med Biol 579:55-97. doi:10.1007/0-387-33778-4-5
112. Arthur JC, Perez-Chanona E, Mühlbauer M et al (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338:120-123. doi:10.1126/science.1224820
113. Wu S, Rhee K-J, Albesiano E et al (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016-1022. doi:10.1038/nm.2015
114. Chichlowski M, Sharp JM, Vanderford DA et al (2008) Helicobacter typhlonius and Helicobacter rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice. Comp Med 58:534-541
115. Iliev ID, Funari VA, Taylor KD et al (2012) Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis. Science 336:1314-1317. doi:10.1126/science.1221789
116. Relton CL, Smith GD (2010) Epigenetic epidemiology of common complex disease: prospects for prediction, prevention, and treatment. PLoS Med. doi:10.1371/journal.pmed.1000356
117. Ventham NT, Kennedy Na, Nimmo ER, Satsangi J (2013) Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 145:293-308. doi:10.1053/j.gastro.2013.05.050
118. Saito S, Kato J, Hiraoka S et al (2011) DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm Bowel Dis 17:1955-1965. doi:10.1002/ibd.21573
119. Dhir M, Montgomery EA, Glöckner SC et al (2008) Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg 12:1745-1753. doi:10.1007/s11605-008- 0633-5
120. Issa JP, Ahuja N, Toyota M et al (2001) Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61:3573-3577 (Pubitemid 32694963)
121. Tao R, de Zoeten EF, Ozkaynak E et al (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13:1299-1307. doi:10.1038/nm1652 (Pubitemid 350073591)
122. Rosen MJ, Frey MR, Washington MK et al (2011) STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. Inflamm Bowel Dis 17:2224-2234. doi:10.1002/ibd.21628
123. Bian Z, Li L, Cui J et al (2011) Role of miR-150-targeting c-Myb in colonic epithelial disruption during dextran sulphate sodium-induced murine experimental colitis and human ulcerative colitis. J Pathol 225:544-553. doi:10.1002/path.2907
124. Wu F, Zikusoka M, Trindade A et al (2008) MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2α. Gastroenterology. doi:10.1053/j.gastro.2008.07.068
125. McKenna LB, Schug J, Vourekas A et al (2010) MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology. doi:10.1053/j.gastro.2010.07.040
126. Bernstein CN, Shanahan F, Weinstein WM (1994) Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343:71-74 (Pubitemid 24019346)
127. Rutter MD, Saunders BP, Wilkinson KH et al (2004) Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53:1813-1816 (Pubitemid 39556902)
128. Rubin CE, Haggitt RC, Burmer GC et al (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. YGAST 103:1611-1620
129. Hoffman A, Kagel C, Goetz M et al (2008) High definition colonoscopy (HD plus) with I-scan function allows to recognize and characterize flat neoplastic changes as precisely as chromoendoscopy. Gastrointest Endosc 67:AB125
130. Wu L, Li P, Wu J et al (2012) The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Colorectal Dis 14:416-420
131. Neumann H, Mönkemüller K, Günther C et al (2012) Advanced endoscopic imaging for diagnosis of Crohn's disease. Gastroenterol Res Pract 2012:301541
132. Kiesslich R, Fritsch J, Holtmann M et al (2003) Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124:880-888 (Pubitemid 36389789)
133. Rutter MD, Saunders BP, Schofield G et al (2004) Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 53:256-260 (Pubitemid 38125515)
134. Kiesslich R, Burg J, Vieth M et al (2004) Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 127:706-713 (Pubitemid 39208403)
135. Kiesslich R, Goetz M, Lammersdorf K et al (2007) Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 132:874-882 (Pubitemid 46440874)
136. Hurlstone DP, Thomson M, Brown S et al (2007) Confocal endomicroscopy in ulcerative colitis: differentiating dysplasia-associated lesional mass and adenoma-like mass. Clin Gastroenterol Hepatol 5:1235-1241 (Pubitemid 47488965)
137. Hurlstone DP, Kiesslich R, Thomson M et al (2007) Confocal chromoscopic endomicroscopy is superior to chromoscopy alone for the detection and characterisation of intraepithelial neoplasia in chronic ulcerative colitis. Gut 57:196-204 (Pubitemid 351158046)
138. Goetz M, Ziebart A, Foersch S et al (2010) In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. Gastroenterology 138:435-446
139. Foersch S, Kiesslich R, Waldner MJ et al (2010) Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy. Gut 59:1046-1055
140. Foersch S, Neufert C, Neurath MF, Waldner MJ (2013) Endomicroscopic imaging of COX-2 activity in murine sporadic and colitis-associated colorectal cancer. Diagn Ther Endosc 2013:250641. doi:10.1155/2013/250641
141. Atreya R, Neumann H, Neufert C et al (2014) In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 20:313-318. doi:10.1038/nm.3462
142. Schürmann S, Foersch S, Atreya R et al (2013) Label-free imaging of inflammatory bowel disease using multiphoton microscopy. Gastroenterology 145:514-516. doi:10.1053/j.gastro.2013.06.054
143. Eaden J, Abrams K, Ekbom A et al (2000) Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 14:145-153 (Pubitemid 30088290)
144. Eaden J (2003) Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2):15-21
145. Bernstein CN, Eaden J, Steinhart AH et al (2002) Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis 8:356-361
146. Brown WA, Farmer KC, Skinner SA et al (2000) 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 45:1578-1584
147. MacGregor DJ, Kim YS, Sleisenger MH, Johnson LK (2000) Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse. Int J Oncol 17:173-179
148. Lindberg B, Persson B, Veress B et al (1996) Twenty years' colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation. Scand J Gastroenterol 31:1195-1204 (Pubitemid 26403095)
149. Herfarth H (2012) The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis. Dig Dis 30(Suppl 2):55-59. doi:10.1159/000341894
150. Tung BY, Emond MJ, Haggitt RC et al (2001) Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134:89-95 (Pubitemid 32096335)
151. Pardi DS, Loftus EV, Kremers WK et al (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. YGAST 124:889-893 (Pubitemid 36389790)
152. Ikegami T, Matsuzaki Y (2008) Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res 38:123-131
153. Eaton JE, Silveira MG, Pardi DS et al (2011) High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 106:1638-1645
154. Van Staa TP, Card T, Logan RF, Leufkens HGM (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54:1573-1578. doi:10.1136/gut.2005.070896 (Pubitemid 41531774)
155. Chan EP, Lichtenstein GR (2006) Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 35:675-712. doi:10.1016/j.gtc.2006.07.003 (Pubitemid 44314185)
156. Biancone L, Petruzziello C, Calabrese E et al (2009) Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis? Gut 58:1703. doi:10.1136/gut.2008.176461
157. Fidder H, Schnitzler F, Ferrante M et al (2009) Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58:501-508. doi:10.1136/gut.2008.163642
158. Caspersen S, Elkjaer M, Riis L et al (2008) Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 6:1212-1217 (quiz 1176)
159. Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807-1816
160. Farraye FA, Odze RD, Eaden J, Itzkowitz SH (2010) AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138:746-774 (774.e1-4; quiz e12-3)